CN105008929B - 预防化学毒性和与年龄相关的疾病的方法和膳食 - Google Patents

预防化学毒性和与年龄相关的疾病的方法和膳食 Download PDF

Info

Publication number
CN105008929B
CN105008929B CN201480008545.5A CN201480008545A CN105008929B CN 105008929 B CN105008929 B CN 105008929B CN 201480008545 A CN201480008545 A CN 201480008545A CN 105008929 B CN105008929 B CN 105008929B
Authority
CN
China
Prior art keywords
protein
subject
diet
meal
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480008545.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105008929A (zh
Inventor
瓦尔特·D·隆哥
塞巴斯蒂安·布兰德霍斯特
摩根·埃利塞·莱文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to CN202111523134.8A priority Critical patent/CN114236130A/zh
Priority to CN201811023405.1A priority patent/CN109187991B/zh
Publication of CN105008929A publication Critical patent/CN105008929A/zh
Application granted granted Critical
Publication of CN105008929B publication Critical patent/CN105008929B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pediatric Medicine (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
CN201480008545.5A 2013-02-12 2014-02-12 预防化学毒性和与年龄相关的疾病的方法和膳食 Active CN105008929B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111523134.8A CN114236130A (zh) 2013-02-12 2014-02-12 用于减轻年龄相关症状的膳食包装
CN201811023405.1A CN109187991B (zh) 2013-02-12 2014-02-12 为受试者提供合理蛋白质膳食的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763797P 2013-02-12 2013-02-12
US61/763,797 2013-02-12
PCT/US2014/016025 WO2014127000A2 (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202111523134.8A Division CN114236130A (zh) 2013-02-12 2014-02-12 用于减轻年龄相关症状的膳食包装
CN201811023405.1A Division CN109187991B (zh) 2013-02-12 2014-02-12 为受试者提供合理蛋白质膳食的方法

Publications (2)

Publication Number Publication Date
CN105008929A CN105008929A (zh) 2015-10-28
CN105008929B true CN105008929B (zh) 2018-10-02

Family

ID=51297596

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480008545.5A Active CN105008929B (zh) 2013-02-12 2014-02-12 预防化学毒性和与年龄相关的疾病的方法和膳食
CN201811023405.1A Active CN109187991B (zh) 2013-02-12 2014-02-12 为受试者提供合理蛋白质膳食的方法
CN202111523134.8A Pending CN114236130A (zh) 2013-02-12 2014-02-12 用于减轻年龄相关症状的膳食包装

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201811023405.1A Active CN109187991B (zh) 2013-02-12 2014-02-12 为受试者提供合理蛋白质膳食的方法
CN202111523134.8A Pending CN114236130A (zh) 2013-02-12 2014-02-12 用于减轻年龄相关症状的膳食包装

Country Status (12)

Country Link
US (3) US9237761B2 (enExample)
EP (2) EP3510875B1 (enExample)
JP (2) JP6885671B2 (enExample)
KR (1) KR20150124962A (enExample)
CN (3) CN105008929B (enExample)
AU (3) AU2014216349B2 (enExample)
BR (1) BR112015019223A2 (enExample)
CA (1) CA2900782C (enExample)
ES (1) ES2807781T3 (enExample)
MX (1) MX382484B (enExample)
RU (2) RU2018141475A (enExample)
WO (1) WO2014127000A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822178T3 (es) * 2012-10-22 2021-04-29 Univ Southern California Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels
AU2014284399B2 (en) * 2013-07-01 2017-10-26 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
RU2687750C2 (ru) 2014-04-02 2019-05-16 Юниверсити Оф Саутерн Калифорния Лечение аутоиммунной реакции и рассеянного склероза
ES2871551T3 (es) 2015-02-12 2021-10-29 Univ Southern California Bloqueadores del receptor de la hormona del crecimiento en la prevención y el tratamiento de enfermedades
CA3108664A1 (en) * 2015-04-16 2016-10-20 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
BR112017023748A2 (pt) * 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
JP2019504073A (ja) * 2016-01-12 2019-02-14 ユニバーシティ オブ サザン カリフォルニア 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
RU2018131403A (ru) 2016-02-15 2020-03-17 Юниверсити Оф Саутерн Калифорния Комбинации лекарственных средств и способы стимуляции эмбрионоподобной регенерации для лечения сахарного диабета и других заболеваний
AU2017261723B2 (en) * 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
AU2019236242A1 (en) * 2018-03-15 2020-10-01 University Of Southern California Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology
EP3801064B1 (en) * 2018-06-07 2024-10-09 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
DE212018000421U1 (de) 2018-07-18 2021-03-01 Andreas Michalsen Auswirkungen einer kurzzeitigen Diät, die Fasten imitiert, auf die Lebensqualität und die Verträglichkeit einer Chemotherapie bei Patientinnen mit Krebs
US20200147112A1 (en) * 2018-10-04 2020-05-14 Meiji Co., Ltd. Diet therapy of intractable cancer and medical diet suitable therefor
CA3119100C (en) 2018-11-09 2024-06-04 Valter D. Longo Nutrition bar for intermittent fasting-mimicking
JP2022530671A (ja) * 2019-04-30 2022-06-30 ユニバーシティ オブ サザン カリフォルニア アルツハイマー病（ａｄ）の介入のための断食模倣食（ｆｍｄ）
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
CN112273641A (zh) * 2019-07-23 2021-01-29 中国科学院上海营养与健康研究所 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法
US20230037534A1 (en) * 2019-12-16 2023-02-09 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
US20230000888A1 (en) * 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
IT202000008740A1 (it) 2020-04-23 2021-10-23 L Nutra Inc Composizione dietetica per l’incremento della massa magra e della massa muscolare
US12029231B2 (en) * 2020-07-13 2024-07-09 L-Nutra Inc. Method for the treatment of depression
IT202000016957A1 (it) 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
EP4190173B1 (en) * 2020-09-23 2024-07-17 Aminovita S.L. Metabolic cancer therapy
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
WO2024044036A1 (en) * 2022-08-23 2024-02-29 University Of Southern California Dietary compositions to extend longevity while maximizing strength and function
US20250194656A1 (en) * 2023-12-14 2025-06-19 L-Nutra Inc. Longevity extending consumable products for maximizing strength and function, methods of consumption and manufacture

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406853B1 (en) * 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
EP1409737A4 (en) * 2001-06-15 2005-10-12 Interleukin Genetics Inc METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050031671A1 (en) * 2003-08-06 2005-02-10 James Johnson Weight management, longevity and health paradigm
MX2007007898A (es) * 2004-12-27 2007-08-20 Nestec Sa Uso de formula para lactantes con contenido de proteina reducido.
MX2008009574A (es) * 2006-02-01 2008-09-04 Nestec Sa Sistema y metodos nutricionales para aumentar la longevidad.
WO2009132320A2 (en) 2008-04-24 2009-10-29 University Of Southern California, Usc Stevens Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
CN101385543A (zh) * 2008-10-23 2009-03-18 上海交通大学 低蛋白食品及其制备方法
CA2779282C (en) * 2009-10-22 2017-12-05 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
ES2822178T3 (es) * 2012-10-22 2021-04-29 Univ Southern California Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels

Also Published As

Publication number Publication date
ES2807781T3 (es) 2021-02-24
CA2900782C (en) 2022-09-27
JP2016509994A (ja) 2016-04-04
RU2674681C2 (ru) 2018-12-12
CN109187991A (zh) 2019-01-11
EP2956776A2 (en) 2015-12-23
CA2900782A1 (en) 2014-08-21
MX2015010320A (es) 2016-06-02
RU2018141475A (ru) 2019-03-21
AU2020200297B2 (en) 2022-04-07
RU2018141475A3 (enExample) 2022-03-29
KR20150124962A (ko) 2015-11-06
MX382484B (es) 2025-03-13
US20160331016A1 (en) 2016-11-17
EP3510875B1 (en) 2020-06-10
CN114236130A (zh) 2022-03-25
CN105008929A (zh) 2015-10-28
EP2956776A4 (en) 2016-12-21
JP2020073473A (ja) 2020-05-14
US20170035094A1 (en) 2017-02-09
CN109187991B (zh) 2021-12-24
US20140227373A1 (en) 2014-08-14
AU2014216349B2 (en) 2019-10-24
AU2020200297A1 (en) 2020-02-06
US9237761B2 (en) 2016-01-19
RU2015134780A (ru) 2017-03-20
AU2014216349A1 (en) 2015-08-06
WO2014127000A2 (en) 2014-08-21
JP6885671B2 (ja) 2021-06-16
HK1212028A1 (en) 2016-06-03
EP3510875A1 (en) 2019-07-17
BR112015019223A2 (pt) 2017-07-18
AU2022202764A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
AU2020200297B2 (en) Methods and diets to protect against chemotoxicity and age related illnesses
Brandhorst et al. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression
Van de Worp et al. Nutritional interventions in cancer cachexia: evidence and perspectives from experimental models
EP2909802B1 (en) Diet formulations promoting tissue/organ regeneration
RU2734774C2 (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
Paoli et al. Not only protein: dietary supplements to optimize the skeletal muscle growth response to resistance training: the current state of knowledge
JP2018516934A (ja) 脂肪量を低減するためのβ−ヒドロキシ−β−メチルブチレート（ＨＭＢ）の組成物および使用方法
Tamer Relationship between diet and seborrheic dermatitis
Hartmann et al. Insulin resistance and Polycystic ovary syndrome (PCOS): part 2. Diet and Nutritional Medicine
Steichen et al. Spermidine content of selected dietary supplements: potential for improvement?
Singh et al. Nutritional modulators in chronic heart failure
HK40002950B (zh) 为受试者提供合理蛋白质膳食的方法
Kowalczuk et al. Intermittent fasting and its influence on health and sports results
HK40002950A (en) Method for providing reasonable protein diet to subject
HK1212028B (en) Methods and diets to protect against chemotoxicity and age related illnesses
Naturopathy Insulin resistance and polycystic ovary syndrome (PCOS): Part 2. Diet and Nutritional Medicine
Japar Fat Fasting: Metabolic Shifting Through Ketone Production and Cellular Renewal
BAWA The feasibility of the use of the Mediterranean diet
Kim Effects of Conjugated Linoleic Acid (CLA) on Skeletal Muscle Metabolism
HK1211723B (en) Diet formulations promoting tissue/organ regeneration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212028

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant